Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels

in European Journal of Endocrinology

The authors and the journal apologise for errors in Figure 2 of the above paper published in the European Journal of Endocrinology 2014 vol 171 Iss 1, pp 59–68. The Bar 3 notes should read 78/121 and Bar 4 notes should be 59%. The correct figure and its legend is published in full below.

Figure 2
Figure 2

The pegvisomant dose required for normalisation of acromegaly disease activity, split by the presence of concomitant diabetes mellitus and its therapy.

Citation: European Journal of Endocrinology 171, 6; 10.1530/EJE-13-0438e

If the inline PDF is not rendering correctly, you can download the PDF file here.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 344 81 1
PDF Downloads 114 62 2
  • View in gallery

    The pegvisomant dose required for normalisation of acromegaly disease activity, split by the presence of concomitant diabetes mellitus and its therapy.